CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: Cellectis bioresearch, a subsidiary of Cellectis Group (Alternext: ALCLS), the genome engineering specialist, announced today a collaboration agreement with Stemgent, Inc. to provide research services that combines mRNA reprogramming technology and genome engineering. The partnership marries Cellectis bioresearch’s leadership in genome engineering with Stemgent’s expertise in cellular reprogramming. Stemgent’s proprietary mRNA reprogramming technology addresses the challenges around deriving non-viral, non-integrating, clinically-relevant induced pluripotent stem (iPS) cells for use in regenerative medicine, drug discovery, and basic research. Traditional reprogramming methods can lead to the integration of unwanted genetic material into the host genome and therefore can be disruptive to the reprogrammed cell’s function.
